IL6 and neoplasm: The M1 phenotype has been attributed pro‐inflammatory and tumour‐suppressive activity, including enhanced antigen presentation through expression of MHC class II [93, 94, 95] and immune cell recruitment through the production of cytokines including tumour necrosis factor‐alpha (TNF‐α), interleukin one beta (IL‐1β), interleukin one alpha (IL‐1α), complement component 1q (C1q), interleukin 6 (IL‐6), interleukin 12 (IL‐12), and CC motif chemokine ligand 2 (CCL2) [96].